Comparison of hydroxyethylstarch 130/0.4 and ringer’s lactate on fibrinogen level in caesarean operations: a randomized clinical trial

Year 2021, Volume: 4 Issue: 2, 166 - 169, 28.03.2021

Nihan Aydın Güzey Havva Esra Uyar Türkyılmaz

https://doi.org/10.32322/jhsm.855395

Abstract

COMPARISON OF HYDROXYETHYLSTARCH 130/0.4 AND RINGER’S LACTATE ON FIBRINOGEN LEVEL IN CAESAREAN OPERATIONS: A RANDOMIZED CLINICAL TRIAL
Background and Aim:
Colloids are effective in volume resuscitation but they have been shown to have negative impacts on fibrin formation. The aim of this study is to evaluate the effect of using low dose HES solutions on fibrinogen level in caserean operations.
Materials and methods:
100 women, scheduled for Caserean surgery with spinal anesthesia were enrolled in the study. Patients were assigned to receive hydroxyethyl starch (HES) 130/0.4 in addition to a basic infusion of Ringer’s lactate (RL) solution (GROUP HES) or exclusively RL solution throughout the intraoperative study period (GROUP RL). Patients in the Group HES received HES 130/0.4 8 ml.kg-1h-1 with RL solution 5 mL.kg-1.h-1 and Group RL received RL solution 20 mL kg-1.h-1. Fibrinogen, haemoglobin, platelet values were recorded preoperatively and at postoperative first hour.
Results:
HES 130/0.4 was used only in Group HES, amount consumed was 418 ± 90 mL. Ringer’s lactate consumption was 276 ± 58 mL for Group HES and 1197 ± 197 mL for Group RL. There was a significant change in haemoglobine and fibrinogen values before and after surgery between groups. The mean decrease in fibrinogen was 92.18 ±60.12 mg/dL in Group HES and 65.70 ± 83.61 mg/dL in Group RL.
Conclusion:
HES 130/0.4 solution can be used in elective Caeserean operations without predicted or active hemorrhage. When there is a hemorrhage of any reason in HES 130/0.4 used cases, the decrease in fibrinogen level must be anticipated and rapid replacement of fibrinogen must be kept in mind.

Keywords

Fibrinogen, Hydroxyethyl starch, caesarean sections

References

• Skhirtladze K, Base EM, Lassnigg A, et al. Comparison of the effects of albümin 5% , hydroxyethylstarch 130/0.46 % and Ringer’s lactate on blood loss and coagulation after cardiac surgery. British Journal of Anaesthesia 2014; 112: 255–64.
• Levi M, Jonge Ed. Clinical relevance of the effects of plasma expanders on coagulation. Semin Thromb Hemost 2007; 33: 810-5.
• Gousheh MR, Akhondzade R, Aghahoseini HA, Olapour A, Rashidi M. The Effects of pre-spinal anesthesia administration of crystalloid and colloid solutions on hypotension in elective cesarean section. Anesth Pain Med 2018; 8: e69446.
• Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5: 266–73.
• Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on‐pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008; 48: 2152–8.
• Krzych LJ, Czempik PF. Hooves better than potatoes: in vitro effects of balanced crystalloid and colloids on functional parameters of coagulation and fibrinolysis. Polish Archives Of Internal Medicine 2017; 127: 209-11.
• Fenger-Eriksen C, Tonnesen E, Ingerslev J, Sorensen B. Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy. J Thromb Haemost 2009; 7: 1099-105.
• Innerhofer P, Fries D, Margreiter J, et al. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation Anesth Analg 2002; 95: 858-65.
• Oshita K, Azma T, Osawa Y, Yuge O. Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 1999; 89: 296–9.
• Mittermayr M, Streif W, Haas T, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration (4). Anesth Analg 2007; 105: 905-17.
• Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004; 139: 552-63.
• Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360–5.